Expression of prostate specific membrane antigen (PSMA) in soft tissue sarcomas and urothelial cell carcinomas: implications for tumour-specific molecular imaging and treatment? - PSMA expression & PSMA PET in soft tissue sarcoma/urothelial cell carcinoma

eids Universitair Medisch Centrum0 个研究点目标入组 120 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Age > 18 years at the time of informed consent.
•Diagnosis of advanced (locally irresectable or metastasized) soft tissue
•sarcoma (cohort 1) or advanced (muscle invasive or metastasized) urothelial
•cell carcinoma (cohort 2).
•Voluntary agreement to provide written informed consent and the willingness and
•ability to comply with all aspects of the protocol.
•Recent (< 8 weeks) standard imaging (with CT or [18F]-FDG PET/CT) with
•measurable disease (lesion diameter > 1 cm).
•Biopsy available of primary tumour and/or metastasis
•WHO performance status of 0-2
•- No previous systemic therapy for advanced soft tissue sarcoma or advanced
•urothelial cell carcinoma, or;
•- Previous systemic therapy for advanced soft tissue sarcoma or advanced
•urothelial cell carcinoma with progression of disease during systemic therapy
•or progression of disease after discontinuation of systemic therapy, or;
•- Previous systemic therapy for advanced soft tissue sarcoma or advanced
•urothelial cell carcinoma with partial response or stable disease, where the
•last dose of systemic therapy was given > 8 weeks before.

•Women who are pregnant and/or lactating.
•Medical or psychiatric conditions that compromise the patient*s ability to give
•informed consent.
•Known hypersensitivity to drugs comparative to [18F]-JK-PSMA-7, any of their
•excipients or to any component of [18F]-JK-PSMA-7.
•Inability to undergo PET/CT scanning, e.g. claustrophobia, weight limits or
•inability to tolerate lying down for the duration of a PET/CT scan (~30

发起方